請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32738
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉文雄(Wen-Hsiung Liu) | |
dc.contributor.author | Ming-Hsu Chen | en |
dc.contributor.author | 陳明煦 | zh_TW |
dc.date.accessioned | 2021-06-13T04:14:30Z | - |
dc.date.available | 2009-07-27 | |
dc.date.copyright | 2006-07-27 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-25 | |
dc.identifier.citation | 參 考 文 獻
中文論文、期刊及書籍 水野卓,川合正允 (賴慶亮)。1997。菇類的化學生化學。國立編譯館,台北,台灣。 中華民國行政院衛生署。九十三年死因統計結果摘要。 王聲遠、蕭明熙。2001 年。開發真菌次級代謝物為醫藥品。Fung. Sci. 16:1-6。 王伯徹。2000 年。具開發潛力食藥用菇介紹。食品工業 32:1~16。 王玉龍。1998。甲羥戊酸多重途徑在人類肝癌細胞細胞株 HepG2 與 Hep3B 之協調及選擇性阻斷之研究。國立陽明大學生物藥學研究所碩士論文。 李奇翰。2001 年。靈芝抗癌效果之研究。國立台灣大學醫事技術學研究所碩士論文。 李儀儂。2004 年。培養條件對靈芝菌絲多醣與其 (1,3; 1,6)-b-D-聚葡萄醣生成量及性質之影響。國立台灣大學食品科技研究所碩士論文。 余竟光、翟云鳳。1979。薄蓋靈芝化學成分之研究。藥物學報 14:374。 林怡朱。2005 年。靈芝不同生長階段液態培養菌絲與子實體之可溶性多醣特性。國立台灣大學園藝研究所碩士論文。 周柏甫。2000 年。探討菌體型態對裂摺菌多醣體生產之影響。國立中央大學化學工程研究所碩士論文。 官振儀、陳漢銘、楊芳鏘。1998。利用酒糟水於靈芝液態培養之研究。第三屆生化工程研討會論文集, 15-18。 洪淑敏。2000。靈芝促進人類肝癌細胞凋亡之研究。國立台灣大學食品科技研究所碩士論文。 郭華仁。2005 年。台灣民族藥學知識及其保護。生物科技法的保護與生命倫理研討會。 陳佩瑜。2002 年。靈芝抗癌成分引發肝癌細胞株凋亡之分子機制研究。國立台灣大學醫事技術學研究所碩士論文。 許瑞祥。1990。靈芝屬菌株鑑定系統之研究。國立台灣大學農業化學研究所博士論文。 許瑞祥。2005 年。靈芝多醣之發現及 70 年代至今之研究回顧 (上)。健康靈芝 30:28-33. 許瑞祥。1988。靈芝的奧秘。正義出版社,台北市。 張東柱。1983。台灣數種靈芝生物學上之研究。國立台灣大學植物病蟲害學研究所碩士論文。 張郁旻。2005 年。靈芝醇抗癌機制之研究:抑制拓樸異構酶及引導肝癌細胞走向老化。國立台灣大學醫事技術學研究所碩士論文。 張明堯。2001。液態培養生產靈芝菌絲體與靈芝多醣最適化之研究。國立海洋大學食品科學研究所碩士論文。 梁志欽。1991。松杉靈芝浸漬發酵培養生產的 1,3-b glucanase 對菌體外多醣之影響。國立台灣大學農業化學研究所碩士論文。 傅昭憲。1991 年。台灣三種靈芝菌之培養性狀、病原性與腐朽之研究。國立台灣大學森林學研究所碩士論文。 葉珮芸。2005 年。台灣原住民藥用植物保肝活性之探討。國立台灣大學農藝學系碩士論文。 楊革。1997。靈芝菌絲體深層培養及多醣提取工藝研究。食用菌 19(2): 8-9。 廖雯慧。2004 年。南方靈芝三萜類抗腫瘤生物活性與藥理功效之研究。國立台灣師範大學生命科學系碩士論文。 賴志穎。2005。靈芝屬菌株锰過氧化酶基因的選殖與表達。國立台灣大學微生物與生化學研究所碩士論文。 英文論文、期刊及書籍 Abugo OO, Nair R, Lakowicz JR. 2000. Fluorescence properties of rhodamine 800 in whole blood and plasma. Anal. Biochem. 279(2):142-150. Baek SJ, Jung WT, Kim DY and Cho KD. 1999. G009: hepatoprotectant, immunostimulant. Drugs Future 24:1068-1071. Bao XF, Liu CP, Fang JN and Li XY. 2001. Structural and immunological studies of a major polysaccharide from spores of Ganoderma lucidum (Fr.) Karst. Carbohy. Res. 332:67-74. Battle J, Ha TZ, Li CF, Dellabeffa V, Rice P, Kalbfleisch J, Browder W, Williams D. 1998. Ligand binging to the (1→3)-beta-D-glucan receptor stimulates NF-kappa B activation, but not apoptosis in U937 cells. Biochem. Biophys. Res. Commun. 249:499-504. Bell SP and Dutta A. 2002. DNA replication in eukaryotic cells. Ann. Rev. Biochem. 71:333-374. Ben-Sasson SA , Gavrieli Y and Sherman Y. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 119:493-501. Boigk G, Stroedter I, Herbst H, Waldschmidt J, Riecken EO, Schuppan D. 1997. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26:643-649. Chang TT and Chou WR. 2004. Antrodia cinnamomea reconsidered and A. salmonea sp. nov. on Cunninghamia konishii in Taiwan. Bot. Bull. Acad. Sin. 45:347-352. Chang UM, Li CH, Lin LI, Huang CP, Kan LS and Lin SB. 2006. Ganoderiol F, a ganoderma triterpene, induces senescence in heptoma HepG2 cells. Life Science in press. Chen MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY and Chen DS. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 336:1855-1859. Chen WC , Hau DM, Wang CC, Lin IH and Lee SS. 1995. Effects of Ganoderma lucidum and Krestin on subset T-cell in spleen of gamma-irradiated mice. Am . J. Chin. Med. 23:71-80. Chiu SW, Wang ZM, Leung TM and Moore D. 2000. Nutritional value of Ganoderma extract and assessment of its genotoxicity and antigenotoxicity using comet assays of mouse lymphocytes. Food Chem. Toxicol. 38:173-178. Choi HS, Sa YS. 2000. Fibrinolytic and antithrombotic protease from Ganoderma lucidum. Mycologia 92:545-552. Chung KS, Kim SB and Chung SH. 1997. Immunoactivities of the protein-polysaccharides of the tips of the growing carpophores of Ganoderma lucidum. Yakhak Hoeji 41:105-110. Cohen GM. 1992. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem. J. 286:331-334. Colins RJ, Harman BV, Gobe GC and Kerr JF. 1992. Internucleosomal DNA Cleavage Should not be the Sole Criterion for Identifying Apoptosis. Int. J. Rad. Biol. 61:451-453. Cuella MJJ, Giner RM, Recio MC, Just MJ, Manez S and Rios JL. 1996. Two fungal lanostane derivatives as phospholipase A2 inhibitors. J. Nat. Prod. 59:977-979. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM and Lotze MT. 1988. NIH conference. Hepatocellular carcinoma. Ann. Intern. Med. 108:390-401. Ekholm SV and Reed SI. 2000. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 12:676-684. Eo SK, Kim YS, Lee CK and Han SS. 1999. Antiviral activities of various water and methanol soluble substances isolated from Ganoderma lucidum. J. Ethnopharmacol. 68:129-136. Feher J, Lang I, Neham KJ, Gergely P and Muzes G. 1990. In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activities in patients. Tokai. Exp. Clin. Med. 15:129-134. Gan KH, Kuo SH and Lin CN. 1998. Steroidal constituents of Ganoderma applanatum and Ganoderma neo-japonicum. J. Nat. Prod. 61:1421-1422. Gan KH, Fann YF, Hsu SH, Kuo KW and Lin CN. 1998. Mediation of the cytotoxicity of lanostanoids and steroids of Ganoderma tsugae through apoptosis and cell cycle. J. Nat. Prod. 61:485-487. GaoYH and Zhou SF. 2003. Cancer prevention and treatment by Ganoderma, a mushroom with medicinal properties. Food reviews international 19:275-325. Gong J and Wang Y. 2002. The kinetic characteristics of mycelium growth of medicinal mushroom Ganoderma sinense in liquid-submerged cultivation. Wei Sheng Wu Xue Bao 42:93-98. Grieve MA. 1981. A modern herb. Vol. 2. Hajjaj H, Mace C, Roberts M, Niederberger P and Fay LB. 2005. Effect of 26-oxygenosterols from Ganoderma lucidum and their activity as cholesterol synthesis inhibitors. Appl. Environ. Microbiol. 71:3652-3658. Harper JW, Burton JL and Solomom MJ. 2002. The anaphase-promoting complex: it’s not only for mitosis anymore. Genes Dev. 16:2179-2206. van der Hem LG, ven der Vliet JA, Bocken CF, Kino K, Hoitsma AJ, Tax WJ. 1995. Ling Zhi-8: studies on a new immunomodulating agent. Transplantation 60:438-443. Hijikata Y and Yamats S. 1998. Effect of Ganoderma lucidum on postherpetic neuralgia. Am. J. Chin. Med. 26:375-381. Hikino H and Mizuno T. 1989. Hypoglycemic actions of some heteroglycans of Ganoderma lucidum fruit bodies. Planta Med. 55:385. Hobbs C. 1992. Milk thistle: the liver herb. Capitola, CA: Botanical. Honda K, Komoda Y and Inoue S. 1988. Sleep-promoting effects of Ganoderma extracts in rats: Comparison between long-term and acute administrations. Tokyo Ika Shika Daigaku Iyo Kizai Kenkyusho Hokuko- Rep. Inst. Med. Dental Eng. (Jpn.) 22:77-82. Hubert EB. 2005. Hepatocellular carcinoma: Therapy and prevention. World J. Gastroenterol. 11(47):7391-7400. Huie CW and Di X. 2004. Chromatographic and electrophoretic methods for Lingzhi pharmacologically active components. J. chromatogr. B 812:241-257. Hung WS, Fang CL, Su CH, Lai WF, Chang YC and Tsai YH. 2001. Cytotoxicity and immunogenicity of sacchachitin and its mechanism of action on skin wound healing. J. Biomed. Mater. Res. 56:93-100. Jacob BP, Dennehy C, Ramirey G, Snapp J and Lawrence VA. 2002. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am. J. Med. 113:506-515. Jiang J, Slivova V, Valachovicova T, Harvey K and Sliva D. 2003. Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. Int. J. Oncol. 24:1093-1099. Johnson RT and Rao PN. 1970. Mammalian cell fusion: Studies on the regulation of DNA synthesis and mitosis. Nature 225:159-164. Kabir Y, Kimura S and Tamura T. 1988. Dietary effect of Ganoderma lucidum mushroom on blood pressure and lipid levels in spontaneously hypertensive rats (SHR). J. Nutr. Sci. Vitaminol. 34:433-438. Kapuscinski J. 1995. DAPI: a DNA specific fluorescent probe. Biotech. Histochem. 70:220. Kerr JFR. 1965. A histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to change in lysosome . J. Pathol. Bateriol. 90:419-435. Kerr JFR. 1971. Shrinkage necrosis: a distinct mode of cellular death. J. Pathol. Bacteriol. 105:13-20. Kim DH, Shim SB, Kim NJ and Jang IS. 1999. Beta-glucuronidase inhibitory activity and hepatoprotective effects of Ganoderma lucidum. Biol. Pharm. Bull. 22:162-164. King RW, Deshaies RJ, Peters JM, and Kirschner MW. 1996. How proteolysis drives the cell cycle. Science 274:1652-1659. Konopski Z, Smeddsrod B, Seljelid R and Eskeland T. 1994. A novel immunomodulator soluble aminated b-1,3-D-glucan: binding characteristics to mouse peritoneal macrophages. Biochim. Biophys. Acta-Mol. Cell. Res. 1221:61-65. Kubota T and Asaka Y. 1982. Structure of ganoderic acid A and B, two new lanostane type bitter triterpenes from Ganoderma lucidum (Fr.) Karst. Helvetica Chimica Acta. 65:611-619. Lee JM, Kwon H, Jeong H, Lee JW, Lee SY, Baek SJ and Surh YJ. 2001. Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother. Res. 15:245-249. Lee SY, Rhee HM. 1990. Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chem. Pharm. Bull. 38:1359-1364. Lei LS and Lin ZB. 1992. Effect of Ganoderma polysaccharides on T cell subpopulation and production of interleukin 2 in mixed lymphocyte response. Acta. Pharm. Sin. 27:331-335. Lei M and Tye BK. 2001. Initiating DNA synthesis: from recruiting to activating the MCM complex. J. cell Sci. 114:1447-1454. Li CH, Chen PY, Chang UM, Kan LS, Fang EH, Tsai KS and Lin SB. 2005. Ganoderic acid X, a lanostanoid triterpene, inhibits topoisomerases and induces apoptosis of cancer cells. Life Science 77:252-265. Lieu CW, Lee SS and Wang SY. 1992. The effect of Ganoderma lucidum on induction of differentiation in leukemic U937 cells. Anticancer Res. 12:1211-1215. Lin CN and Tome WP. 1991. Novel cytotoxic priciples of Formosan Ganoderma lucidum. J. Nat. Prod. 543:998-1002. Lin JM, Lin CC, Chen MF, Ujiie T and Takada A. 1995. Radical scavenger and antihepatotoxic activity of Ganoderma formosanum, Ganoderma lucidum and Ganoderma neo-japonicum. Journal of Ethnopharmacology 47:33-41. Lin WH, Hung CH, Hsu CI and Lin JY. 1997. Dimerization of the N-terminal amphipathic alpha-helix domain of the fungal immunomodulatory protein from Ganoderma tsugae (Fip-gts) difined by a yeast two hybrid system and site directed mutagenesis. J. Biol. Chem. 272:20044-20048. Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M and Scott MP. 2004. Molecular cell biology, 5e. Chapter 21, p855. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. 2001. Prevention of the development of N,N’-dimethylhydrazine-induced colon tumors by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male ICR mice. Int. J. Mol. Med. 9:113-117. Luper S. 1998. A review of plants used in the treatment of liver disease: Part 1. Altern. Med. Rev. 3:410-421. Macdonald GA. 2001. Pathogenesis of heptacellular carcinoma. Clin Liver Dis. 5:69-85. Masui Y. 2001. From oocyte maturation to the in vitro cell cycle: the history of discoveries of maturation-promoting factor (MPF) and cytostatic factor (CSF). Differentiation. 69:1-17. Mothana R, Jansen R, Julich WD, Lindequist U. 2000. Ganomycin A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma. J. Nat. Pro. 63:416-418. Nakamura N, Hirakawa A, Gao JJ, Kakuda H, Shiro M, Komatsu Y, Sheu CC and Hattori M. 2004. Five new maleic and succinic acid derivatives from the mycelium of Antrodia camphorata and their cytotoxic effects on LLC tumor cell line. J. Nat. Prod. 67:46-48. Nurse P. 2002. Cyclin dependent kinases and cell cycle control. (Nobel Lecture) Chembiochem. 3:596-603. Okuda K. 2002. Hepatocellular carcinoma-history, current status and perspectives. Dig. Liver Dis. 34:613-616. Osborn AJ, Elledge SJ, and Zou L. 2002. Checking on the fork: the DNA-replication stress-response pathway. Trends Cell Biol. 12:509-516. Pan J, Cao X, Li F, Zuo Z, Sun Q and Wang L. 1996. Studies on the nutritional requirement of Ganoderma lucidum in submerged culture. Acta Edulis Funji 3(4):31-34. Parkin DM. 2001. Global cancer statistics in the year 2000. Lancet Oncol. 2:533-543. Parkin DM, Stjernsward J and Muir CS. 1984. Estimates of the worldwide frequency of twelve major cancers. Bull. World Health Organ. 62:163-182. Pilotti CA. 2005. Stem rots of oil palm caused by Ganoderma boninense: Pathogen biology and epidemiology. Mycopathologia 159:129-137. Tanaka S, Ko K, Kino K, Tsuchiya K, Yamashita A, Murasugi A, Sakuma S, Tsunoo H. 1989. Complete amino acid sequence of an immunomodulatory protein, ling zhi-8 (LZ-8). An immunomodulator from a fungus, Ganoderma lucidum, having similarity to immunoglobulin variable regions. J. Biol. Chem. 264:16372-16377. Toth JO, Luu B, Beck JP and Ourisson G. 1983. Cytotoxic triterpenes from Ganoderma lucidum (Polyporaceae): Structures of ganoderic acids U-Z. J. Chem. Res. (S):299. Tuchweber B, Sieck R, Trost W. 1979. Prevention of silybin of phalloidin induced acute hepatoxicity. Toxicol. Appl. Pharmacol. 51:265-275. Safary A and Berk J. 2000. Vaccination against hepatitis B: Current challeges for Asian countries and future directions. Journal of Gastroenterology and Hepatology 15:396-401. Singh RP and Agarwal R. 2004. A chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutation Research 555:21-32. Singh RP and Agarwal R. 2005. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur. J. Cancer 41:1969-1979. Shah JV and Cleveland DW. 2000. Waiting for anaphase: Mad2 and the spindle assembly checkpoint. Cell. 103:997-1000. Shao MS. 2003. Natural products of the medicinal fungus Ganoderma lucidum: Occurrence, Biological activities, and Pharmacological functions. The chemical record 3:172-180. Sherlock S and Dooley J. 1996. Virus hepatitis. In: Disease of the liver and biliary system, 10th ED, Oxiford: Blackwell science 274-285. Sherr CJ. 2000. Cell cycle control and cancer. Harvey Lect. 96:73-92. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD and Murray CJL. 2002. Global and regional estimates of cancer mortality and incidence by site. II. Results for the global burden of disease. 2000. BMC Cancer. 2: 37. Shimizu A, Yano T, Saito Y and Inada Y. 1985. Chem. Pharm. Bull. 33:3012. Sone Y, Okuda R, Wada N, Kishida E and Misaki A. 1985. Structure and antitumor activities of the polysaccharide isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum. Agric. Biol. Chem. 49(9):2641-2653. Su HJ, Fang YF, Chung MI, Won SJ and Lin CN. 2000. New lanostanoids of Ganoderma tsugae. J. Nat. Prod. 63:514-516. Tanaka S, Ko K, Kino K, Tsuchiya K, Yamashita A, Murasugi A, Sakuma S, and Tsunoo H. 1989. Complete amino acid sequence of an immunomodulatory protein, ling zhi-8 (LZ-8). An immunomodulator from a fungus, Ganoderma lucidum, having similarity to immunoglobulin variable regions. J. Biol. Chem. 264:16372-16377. Varghese L, Agarwal C, Tyagi A, Singh RP and Agarwal R. 2005. Silibinin efficacy against human hepatocellular carcinoma. Clin. Cancer Res. 23:8441-8448. Wan F and Huang D. 1992. Anti-inflammatory and analgesic actions of artifitial and fermentative Ganoderma sinense. Zhongguo Zhong Yao Za Zhi 17:619-622. Wasser SP and Weis AL. 1999. Therapeutic effects of substances occurring in higher basidiomycetes mushrooms: a modern perspective. Crit. Rev. Immunol. 19:65-96. Werner GH and Jolles P. 1996. Immunostimulating agents-what next-a review of their present and potential medical applications. Eur. J. Biochem. 242:1-19. Wu TS, Shi LS and Kuo SN. 2001. Cytotoxicity of Ganoderma lucidum triterpenes. J. Nat. Prod. 64:1121-1122. Wyllie AH. 1980. Glucocorticoid-induced thymocyte apoptosis is associate with endogenous endonuclease activation. Nature 284:555-556. Yang HL. 2005. Ganoderic acid produced from submerged culture of G. lucidum induces cell cycle arrest and cytotoxicity in human hepatoma cell line BEL7402. Biotechnol. Lett. 27:835-838. Yu JG, Chen RY, Yao ZX, Zhai YF, Yang SL and Ma JL. 1990. Studies on constituents of ganoderma capense IV. The chemical structures of ganoine, ganodine and ganoderpurine . Yaoxue Xuebae 25:612-616. Zhang N, Hartig H, Dzhagalov I, Draper D and He YW. 2005. The role of apoptosis in the development and function of T lymphocytes. Cell Res. 15:749-769. Zhong JJ and Tang YJ. 2004. Submerged cultivation of medical mushrooms for production of valuable bioactive metabolites. Adv. Biochem. Eng. Biotechnol. 87:25-59. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32738 | - |
dc.description.abstract | 台灣紫芝為台灣地區特有之靈芝品種,目前關於此菌株之文獻及研究報告相當稀少。本研究之目的為建立台灣紫芝於五公升醱酵槽中之最適液態醱酵條件,評估醱酵產物之抗腫瘤活性,及純化最具有生物活性之成分。藉由台灣紫芝在 500 mL Hinton 氏三角瓶培養之結果,選出具有生產較多菌絲體及生物活性代謝物潛力之 G. formosanum ATCC76538 做為生產菌株。在五公升醱酵槽中探討生產菌絲體及胞外多醣之最適接種量、攪拌速率、通氣量之結果為: 最適接種量 10%, 最適攪拌速率 150 rpm, 最適通氣量 1 vvm。醱酵濾液以乙酸乙酯進行萃取,所得之萃取物在細胞測試中對肺纖維母細胞 (MRC-5)、肝癌細胞 (Hep3B、HepG2)、子宮頸癌細胞 (HeLa)、肺癌細胞 (CL1-1) 均有明顯抑制生長之效果,進一步之研究發現紫芝萃取物或許能經由粒腺體依賴性細胞凋亡路徑誘發 Hep3B 細胞進行細胞凋亡。由醱酵液萃取物純化所得之活性物質 F4652,在劑量增加下可明顯對 Hep3B 細胞之生長產生抑制。利用固相萃取法及半製備式管柱加速 F4652 之純化流程,並以 GC-MS 分析其分子量。 | zh_TW |
dc.description.abstract | Ganoderma fromosanum is a unique Ganoderma sp. in Tawain. Until now, there have been just a few literatures and studies on this strain. The purpose of this study is to optimize the fermentation conditions of G. formosanum in a 5-L fermentor, to evaluate the antitumor effect of fermentation products and to purify the the most biological active component. We chose G. formosanum ATCC76538 as the production strain because it showed more potential on mycelia growth and bioactive metabolites production in a 500 mL Hinton flask cultivation. The effect of inoculum size, agitation speed, aeration rate on production of biomass and extracellular polysaccharide were carried out in a 5-L fermentor. As it was found that the optimal cultivation conditions were as follows: inoculum size, 10%; agitation speed, 150 rpm; aeration rate, 1vvm. The fermentation filtrate was extracted with ethylacetate and the extract showed significant growth inhibition to human lung fibroblast cell (MRC-5)、hepatocellular carcinoma cell (Hep3B)、hepatoblastoma cell (HepG2)、cervix epithelial carcinoma cell (HeLa) and lung carcinoma cell (CL1-1). Further investigation showed the extract might induce apoptosis in Hep3B cell through mitochondria dependent pathway. An active compound F4652 was purified from filtrate extract, and showed growth inhibiton against Hep3B cells in a dose-dependent manner. We used solid-phase extraction and semi-preparative column to fasten the purification process and used GC-MS to analyze the molecular weight of F4652. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T04:14:30Z (GMT). No. of bitstreams: 1 ntu-95-R93b47106-1.pdf: 1133552 bytes, checksum: 9083998e89444678a5986b5b80451ba3 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 中文摘要 ……………………………………………………. I
英文摘要 ……………………………………………………. II 目 錄 ……………………………………………………. III 表 次 ……………………………………………………. V 圖 次 ……………………………………………………. VI 縮寫表 ……………………………………………………. VIII 第一章 緒 言 ………………………………………………. 1 第一節 肝疾病研究之重要性 ………………………....... 1 第二節 靈芝及台灣紫芝 ……………………………....... 4 第三節 細胞週期與細胞凋亡 ………………………....... 13 第四節 研究動機與目的 ………………………………... 23 第二章 材 料 與 方 法 …………………………………... 26 第一節 材料 ……………………………………………... 26 第二節 方法 ……………………………………………... 28 第三節 藥品 …………………………………………....... 36 第四節 儀器 ……………………………………………... 37 第三章 結 果 ………………………………………………. 39 第一節 以深部培養進行台灣紫芝菌株生長及生物活性代謝物生產之比較 ……………………………….. 39 第二節 台灣紫芝菌絲體及胞外多醣於五公升醱酵槽中最適醱酵條件之檢討 …………………………….. 42 第三節 以層析法分析台灣紫芝生物活性代謝物 …….. 47 第四節 以人類細胞株評估台灣紫芝生物活性代謝產物之抗腫瘤功能 …………………………………….. 51 第五節 台灣紫芝生物活性代謝產物誘發人類肝癌細胞 Hep3B 進行細胞凋亡之確認 …………………. 55 第六節 台灣紫芝生物活性代謝物之純化及鑑定 ……… 63 第四章 討 論 ……………………………………………….. 83 第五章 結 論 ……………………………………………….. 106 參 考 文 獻 ………………………………………………… 108 | |
dc.language.iso | zh-TW | |
dc.title | 台灣紫芝生物活性代謝產物之醱酵生產與功能評估 | zh_TW |
dc.title | Production and functional evaluation of bioactive metabolites using submerged culture of Ganoderma formosanum | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蔡英傑(Ying-Chieh Tsai),李重義(Chung-Yi Lee),孟孟孝(Meng-Hsiao Meng),李昆達(Kung-Ta Lee) | |
dc.subject.keyword | 靈芝,台灣紫芝,醱酵,液態培養,生物活性代謝產物,細胞凋亡, | zh_TW |
dc.subject.keyword | Ganoderma,Ganoderma formosanum,fermentation,submerged culture,bioactive metabolites,apoptosis, | en |
dc.relation.page | 118 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-25 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 微生物與生化學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 1.11 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。